Exelixis Drug Patent Portfolio
Exelixis owns 1 orange book drug protected by 7 US patents Given below is the list of Exelixis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11298349 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | 10 Feb, 2032 | Active |
| US9717720 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | 10 Feb, 2032 | Active |
| US8877776 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | 08 Oct, 2030 | Active |
| US11091439 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | 15 Jan, 2030 | Active |
| US11091440 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer | 15 Jan, 2030 | Active |
| US11098015 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | 15 Jan, 2030 | Active |
| US7579473 | c-Met modulators and methods of use | 14 Aug, 2026 | Active |
Latest Legal Activities on Exelixis's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Exelixis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Apr, 2022 | US8877776 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Apr, 2022 | US11298349 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Apr, 2022 | US11298349 |
|
Email Notification
Critical
| 24 Mar, 2022 | US11298349 |
|
Issue Notification Mailed
Critical
| 23 Mar, 2022 | US11298349 |
|
Application Is Considered Ready for Issue
Critical
| 18 Mar, 2022 | US11298349 |
| Dispatch to FDC | 18 Mar, 2022 | US11298349 |
|
Email Notification
Critical
| 10 Mar, 2022 | US11298349 |
|
Mail Response to 312 Amendment (PTO-271)
Critical
| 10 Mar, 2022 | US11298349 |
|
Response to Amendment under Rule 312
Critical
| 04 Mar, 2022 | US11298349 |
|
Pubs Case Remand to TC
Critical
| 01 Mar, 2022 | US11298349 |
|
Email Notification
Critical
| 28 Feb, 2022 | US11298349 |
| Mail PUB other miscellaneous communication to applicant | 28 Feb, 2022 | US11298349 |
|
Amendment after Notice of Allowance (Rule 312)
Critical
| 28 Feb, 2022 | US11298349 |
| PUB Other miscellaneous communication to applicant | 24 Feb, 2022 | US11298349 |
Exelixis Drug Patents' Oppositions Filed in EPO
Exelixis drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 05, 2013, by Actavis Group Ptc Ehf. This opposition was filed on patent number EP10701175A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP12704492A | Aug, 2022 | STADA Arzneimittel AG | Revoked |
| EP10701175A | Dec, 2013 | Ladendorf, Oliver | Patent maintained as amended |
| EP10701175A | Dec, 2013 | Gallafent, Alison | Patent maintained as amended |
| EP10701175A | Dec, 2013 | Actavis Group PTC ehf | Patent maintained as amended |
Exelixis's Family Patents
Exelixis drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 23.9% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Exelixis Drug List
Given below is the complete list of Exelixis's drugs and the patents protecting them.
1. Cometriq
Cometriq is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11298349 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
10 Feb, 2032
(7 years from now)
| Active |
| US9717720 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
10 Feb, 2032
(7 years from now)
| Active |
| US8877776 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
08 Oct, 2030
(5 years from now)
| Active |
| US11091439 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
15 Jan, 2030
(5 years from now)
| Active |
| US11091440 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
15 Jan, 2030
(5 years from now)
| Active |
| US11098015 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
15 Jan, 2030
(5 years from now)
| Active |
| US7579473 | c-Met modulators and methods of use |
14 Aug, 2026
(1 year, 7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cometriq's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List